Literature DB >> 28496851

Age as a Risk Factor for Stroke in Atrial Fibrillation Patients: Implications in Thromboprophylaxis in the Era of Novel Oral Anticoagulants.

Konstantina Mitrousi1, Gregory Y H Lip1, Stavros Apostolakis1.   

Abstract

Atrial fibrillation is associated with significant morbidity and mortality. There is a strong relationship between atrial fibrillation and aging, thromboembolism, stroke, congestive heart failure and hypertension. In addition, advanced age is a powerful risk factor for stroke and thromboembolism in patients with atrial fibrillation. For many years, vitamin K antagonists were the only approved anticoagulants for the management of atrial fibrillation. Lately new anticoagulants made their appearance and large trials have already shown their superiority against vitamin K antagonists. Since the arrhythmia is encountered frequently in the elderly, it is crucial to identify the beneficial effects of the novel oral anticoagulants in this particular patient population.

Entities:  

Keywords:  Atrial Fibrillation; age; risk prediction; stroke; systemic embolism

Year:  2013        PMID: 28496851      PMCID: PMC5153060          DOI: 10.4022/jafib.783

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  43 in total

1.  Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.

Authors:  Amitava Banerjee; Deirdre A Lane; Christian Torp-Pedersen; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2011-12-21       Impact factor: 5.249

Review 2.  Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.

Authors:  Alexander G G Turpie; Reinhold Kreutz; Juan Llau; Bo Norrving; Sylvia Haas
Journal:  Thromb Haemost       Date:  2012-09-26       Impact factor: 5.249

3.  Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).

Authors:  Christian T Ruff; Robert P Giugliano; Elliott M Antman; Sharon E Crugnale; Tomas Bocanegra; Michele Mercuri; James Hanyok; Indravadan Patel; Minggao Shi; Dan Salazar; Carolyn H McCabe; Eugene Braunwald
Journal:  Am Heart J       Date:  2010-10       Impact factor: 4.749

4.  Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study.

Authors:  G Palareti; J Hirsh; C Legnani; C Manotti; A D'Angelo; V Pengo; M Moia; G Guazzaloca; S Musolesi; S Coccheri
Journal:  Arch Intern Med       Date:  2000-02-28

Review 5.  A review of oral anticoagulants in patients with atrial fibrillation.

Authors:  Arnold J Greenspon
Journal:  Postgrad Med       Date:  2012-11       Impact factor: 3.840

6.  Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range.

Authors:  Stuart J Connolly; Janice Pogue; John Eikelboom; Gregory Flaker; Patrick Commerford; Maria Grazia Franzosi; Jeffrey S Healey; Salim Yusuf
Journal:  Circulation       Date:  2008-10-27       Impact factor: 29.690

7.  Risk for systemic embolization of atrial fibrillation without mitral stenosis.

Authors:  H S Cabin; K S Clubb; C Hall; R A Perlmutter; A R Feinstein
Journal:  Am J Cardiol       Date:  1990-05-01       Impact factor: 2.778

8.  Risk factors for stroke and other embolic events in patients with nonrheumatic atrial fibrillation.

Authors:  K M Flegel; J Hanley
Journal:  Stroke       Date:  1989-08       Impact factor: 7.914

9.  Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study.

Authors:  Claudia Stöllberger; Pavel Chnupa; Christine Abzieher; Thomas Länger; Josef Finsterer; Igor Klem; Elisabeth Hartl; Cornelius Wehinger; Barbara Schneider
Journal:  Clin Cardiol       Date:  2004-01       Impact factor: 2.882

10.  Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.

Authors:  W M Feinberg; J L Blackshear; A Laupacis; R Kronmal; R G Hart
Journal:  Arch Intern Med       Date:  1995-03-13
View more
  4 in total

1.  Efficacy and Safety of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and High Thromboembolic Risk. A Systematic Review.

Authors:  Domenico Acanfora; Marco Matteo Ciccone; Pietro Scicchitano; Giovanni Ricci; Chiara Acanfora; Massimo Uguccioni; Gerardo Casucci
Journal:  Front Pharmacol       Date:  2019-09-19       Impact factor: 5.810

2.  Switching to Another Oral Anticoagulant and Drug Discontinuation Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Different Direct Oral Anticoagulants.

Authors:  Christine L Baker; Amol D Dhamane; Jigar Rajpura; Jack Mardekian; Oluwaseyi Dina; Cristina Russ; Lisa Rosenblatt; Melissa Lingohr-Smith; Jay Lin
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

3.  Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants.

Authors:  Gregory Y H Lip; Richard R Murphy; Farhad Sahiar; Timothy J Ingall; Amol D Dhamane; Mauricio Ferri; Patrick Hlavacek; Madison T Preib; Allison Keshishian; Cristina Russ; Lisa Rosenblatt; Huseyin Yuce; Steven Deitelzweig
Journal:  JAMA Netw Open       Date:  2022-08-01

4.  Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation.

Authors:  Ole-Christian Walter Rutherford; Christian Jonasson; Waleed Ghanima; Fabian Söderdahl; Sigrun Halvorsen
Journal:  Heart       Date:  2021-05-11       Impact factor: 5.994

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.